SINK COVID-19 study: Can common drugs offer 2-step approach to combat deadly virus?

Beaumont News Releases
04 May 2020
https://www.beaumont.org/health-wellness/press-releases/sink-covid-19-study-can-common-drugs-offer-2-step-approach-to-combat-deadly-virus

Researchers at Beaumont Hospital, Royal Oak have begun enrolling patients in a new clinical study aimed at treating COVID-19 patients with two common drugs – naltrexone and ketamine. It’s called SINK COVID-19, or the Study of Immunomodulation using Naltrexone and Ketamine for COVID-19.

Medicine specialist talks treatments for lingering COVID-19 symptoms

WWBT
03 March 2021
https://www.nbc12.com/2021/03/04/medicine-specialist-talks-treatments-lingering-covid-symptoms/

Functional medicine specialist Dr. Aaron Hartman says the solution to potentially treating Long-COVID isn’t new. He’s been following evidence that suggests that using a low dose of a drug called naltrexone, which is typically used for a drug overdose, could improve the condition.

Got Inflammation? How LDN can help in the times of Covid-19.

Rhyena Halpern
20 May 2020
https://rhyhalpern.medium.com/got-inflammation-how-ldn-can-help-in-the-times-of-covid-ac9694ad1b29

There is something you can do to help lower the inflammation in your cells, organs and body. It is a prescribed drug called LDN. LDN, or low dose naltrexone, is used to relieve people from chronic, non-responsive pain that results from inflammation. LDN works by staying in the body for a very short time, supporting the body’s ability to produce endorphins and to kick start the immune system into gear. (High dose naltrexone does not work in the body the same way.) Of course, a healthy diet of low inflammatory, nutrient dense foods, lotsa rest, supplementation and mindfulness also rounds out the picture of optimal wellness.

Phase 2 Trial to Evaluate Safety and Efficacy of CYTO-205 in Mild COVID-19

ClinicalTrials.gov
13 January 2021
https://www.clinicaltrials.gov/ct2/show/NCT04708327?term=Cytocom&draw=2&rank=1

The aim of the study is to assess the safety and clinical efficacy of low-dose naltrexone (CYTO-205; Cytocom, Inc) in reducing the proportion of higher risk patients who progress from mild COVID-19 to a more severe disease category.

Low-Dose Naltrexone for Fibromyalgia and ME/CFS

Verywell Health
04 November 2020
https://www.verywellhealth.com/low-dose-naltrexone-ldn-for-fibromyalgia-cfs-716070

A series of Stanford University studies have shown as much as a 30% decline fibromyalgia symptoms compared to placebo. Researchers say results are best in people with higher sedimentation rates, which indicates an inflammatory response. Results also indicate that the drug is well tolerated. However, these studies have all been small and more work needs to be done before we know how safe and effective LDN is for this condition.